Despite their clinical success, real-world data suggest that GLP-1 receptor agonists may be limited by challenges, driving interest in complementary mechanisms that target the underlying metabolic ...

Persistent mycobacterial infections may depend on senescent macrophages that provide a long-term intracellular refuge to ...

Ningbo Jiefu Biotechnology Co. Ltd. has identified new epidermal growth factor receptor (EGFR; ERBB1; HER1) inhibitors and EGFR protein/nucleic acid degraders potentially useful for the treatment of ...

Vinci Pharmaceuticals Inc. has closed a series A financing round raising over $8 million as the company advances development of its Epiplant delivery platform.

Simcere Pharmaceutical Co. Ltd. has divulged bicyclic compounds acting as lysosomal acid glucosylceramidase (GBA; β-glucocerebrosidase) positive allosteric modulators reported to be useful for the ...

Mitochondrial dysfunction in astrocytes is a driver of Parkinson’s disease (PD), but its upstream modulators are not well identified. Mendelian randomization and single-cell transcriptomic analysis ...

Glaukos Corp. has signed an exclusive license agreement with Revopsis Therapeutics Inc. to develop and commercialize RO-104, a novel trispecific biologic for the treatment of neovascular age-related ...

Editas Medicine Inc. has received approval in Australia to initiate a first-in-human trial of EDIT-401 in patients with heterozygous familial hypercholesterolemia. The phase I/II Strive trial has ...

Viatris Inc. plans to discuss the buyout of Pacira Biosciences Inc. during its third-quarter earnings call Nov. 5, but the ...

Worldwide drug approvals totaled 38 in August 2026, compared to 39 in August 2025 and 52 in August 2024. Through the first eight months of 2026, global approvals totaled 337, down 6.4% from 360 during ...

The FDA has awarded orphan drug designation to Vtv Therapeutics Inc.’s HPPD (HPP-8668), an investigational, oral, first-in-class Nrf2/Bach1 modulator, for sickle cell disease.

Huadong Medicine presented data for DD-1013, a novel long-acting GLP-1/GIP/amylin receptor triple agonist that was tested in vitro and in vivo for obesity management in diet-induced obese rats.